We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| China Medical Technologies ADS, Each Representing 10 Ordinary Shares (MM) | NASDAQ:CMED | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.82 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
BEIJING, Jan. 31, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it will report its unaudited financial results for the third fiscal quarter ended December 31, 2010 before the U.S. market opens on February 18, 2011. The Company's 2010 fiscal year ends on March 31, 2011.
The Company's senior management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on February 18, 2011 (9:00 p.m. Beijing/Hong Kong time on February 18, 2011).
Conference Call
The dial-in details for the live conference call are as follows:
- U.S. Toll Free Number 1-866-783-2141 | |
- International Dial-in Number 1-857-350-1600 | |
Passcode: CMEDCALL | |
A live webcast of the conference call will be available on http://ir.chinameditech.com.
A replay of this webcast will be available for one month on this website.
A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. U.S. Eastern Time on February 19, 2011. The dial-in details for the replay are as follows:
- U.S. Toll Free Number 1-888-286-8010 | |
- International Dial-in Number 1-617-801-6888 | |
Passcode: 46276526 | |
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.
Contact | |
Winnie Yam | |
Tel: +852-2511-9808 | |
Email: IR@chinameditech.com | |
SOURCE China Medical Technologies, Inc.
Copyright 2011 PR Newswire
1 Year China Medical Chart |
1 Month China Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
